Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc has seen a significant increase in its estimated market value, now projected to be $4.44 billion, driven by an accelerated timeline for the approval and commercialization of its product Axpaxli. The company's strategic regulatory changes may allow for an expedited NDA filing, potentially shaving off over a year from the timeline, with an anticipated FDA decision by early 2027. This advancement underlines the strong demand for more durable ophthalmic therapies and highlights the potential for enhanced market positioning against competitors like EYPT's Duravyu.

Bears say

Ocular Therapeutix Inc has experienced significant financial losses since its inception, which raises concerns about its long-term viability and ability to sustain operations. The company faces substantial market competition from existing and emerging therapies, which could hinder its market penetration and impact pricing strategies. Additionally, potential delays in clinical development, regulatory approvals, and commercialization efforts could exacerbate financial pressures by resulting in prolonged development timelines and increased costs.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.